Elosulfase Alfa
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Elosulfase Alfa: From Morquio A Syndrome to Scheie Syndrome
One-Sentence Summary
Elosulfase alfa (VIMIZIM) is an enzyme replacement therapy, recombinant GALNS, used for Morquio A syndrome (MPS IVA). The TxGNN model predicts it may be effective for Scheie syndrome (attenuated MPS I), but there are 0 clinical trials and only 2 general MPS cohort publications, and none of the evidence tests the drug in this disease. The high score most likely reflects the two diseases’ shared MPS class in the knowledge graph rather than a real drug-disease link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Morquio A syndrome (MPS IVA); the US license text is blank in the source data, so this is taken from the literature and mechanism notes |
| Predicted New Indication | Scheie syndrome |
| TxGNN Prediction Score | 99.90% (model rank 3363) |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (BLA125460) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the source record. Elosulfase alfa is a recombinant N-acetylgalactosamine-6-sulfatase (GALNS). It degrades keratan sulfate and chondroitin-6-sulfate, which build up in Morquio A syndrome.
Scheie syndrome is a different disease. It is the attenuated form of MPS I, caused by IDUA (alpha-L-iduronidase) deficiency, and it accumulates dermatan sulfate and heparan sulfate. Elosulfase alfa does not act on these substrates, so there is no substrate overlap and no direct mechanistic rationale.
The prediction therefore looks like a graph-proximity artifact: both diseases are mucopolysaccharidoses, and the model likely links them through that shared class. No clinical data support the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35005816 | 2022 | Cohort | Human Mutation | Molecular characterization of 302 Iranian MPS patients (289 families) using NGS panel and Sanger sequencing. A diagnostic and genetic study with no treatment data. |
| 18584975 | 2009 | Cohort | Pathologie-Biologie | Clinical features and consanguinity in MPS I and MPS IVA patients in Tunisia. Descriptive only, with no evaluation of elosulfase alfa. |
Both papers are general MPS epidemiology or genetics studies. Neither tests elosulfase alfa in Scheie syndrome.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| BLA125460 | VIMIZIM | Injection, solution, concentrate (injectable) | BioMarin Pharmaceutical Inc. |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Elosulfase alfa cleaves different substrates (keratan sulfate and chondroitin-6-sulfate) from those that accumulate in Scheie syndrome (dermatan and heparan sulfate). There are no trials and no supporting literature, so this is an L5 model-only prediction with a likely graph artifact behind the score.
To proceed, the following is needed:
- Preclinical evidence, such as in vitro or animal data, that GALNS can affect dermatan or heparan sulfate turnover. Absent that, the mechanism argues against pursuing this indication.
- Package insert safety data (warnings and contraindications), which are currently missing.
- Detailed mechanism of action data from DrugBank.
Note on other predictions: The rank 2 prediction, “lysosomal storage disease with skeletal involvement,” includes Morquio A syndrome. That is elosulfase alfa’s own approved use, so it is on-label rather than repurposing. Evidence there supports Morquio A only and should not be extended to other skeletal lysosomal storage diseases without disease-specific data.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.